Search

Meeting Coverage:

Association for Research in Vision & Ophthalmology

ARVO: 2020

HtrA1 Inhibition for Dry AMD

Dante J. Pieramici, MD

Show Description +

Dante Pieramici, MD, explains potential benefits to targeting HtrA1 protein in patients with dry AMD. Dr. Pieramici outlines the structure and results of a phase 1 trial that sought to evaluate the safety of an anti-HtrA1 agent in patients with geographic atrophy secondary to dry AMD.

Posted: 5/13/2020

Keywords:

Clinical Cases

•

Dry age-related macular degeneration (Dry AMD)

•

retina-meeting-recap

Up Next

OPTIC Study Data

OPTIC Study Data

Arshad M. Khanani, MD

PALADIN Study in Diabetic Eye Disease

PALADIN Study in Diabetic Eye Disease

Victor H. Gonzalez, MD

Clinical Trials Evaluating IONIS-FB-Lrx

Clinical Trials Evaluating IONIS-FB-Lrx

Glenn Jaffe, MD

Brolucizumab and Aflibercept in HAWK and HARRIER

Brolucizumab and Aflibercept in HAWK and HARRIER

Rishi P. Singh, MD

Phase 1/2A Data on Transplantation of hESC-Derived RPE Cells for Dry AMD

Phase 1/2A Data on Transplantation of hESC-Derived RPE Cells for Dry AMD

Christopher D. Riemann, MD

100-Week Data vs. 52-Week Data in PANORAMA

100-Week Data vs. 52-Week Data in PANORAMA

Jennifer I. Lim, MD

Retinal Nonperfusion Status in Patients with DME

Retinal Nonperfusion Status in Patients with DME

Charles C. Wykoff, MD, PhD

Real-World RVO Treatment Outcomes

Real-World RVO Treatment Outcomes

Thomas A. Ciulla, MD, MBA

Novel C5 Inhibitor for GA Growth

Novel C5 Inhibitor for GA Growth

Karl Csaky, MD, PhD

Back to All Videos

HtrA1 Inhibition for Dry AMD

Dante J. Pieramici, MD

Dante Pieramici, MD, explains potential benefits to targeting HtrA1 protein in patients with dry AMD. Dr. Pieramici outlines the structure and results of a phase 1 trial that sought to evaluate the safety of an anti-HtrA1 agent in patients with geographic atrophy secondary to dry AMD.

Posted: 5/13/2020

Keywords:

Clinical Cases

•

Dry age-related macular degeneration (Dry AMD)

•

retina-meeting-recap

Please log in to leave a comment.

More From ARVO: 2020 Coverage

Real-World RVO Treatment Outcomes

Real-World RVO Treatment Outcomes

Thomas A. Ciulla, MD, MBA

Novel C5 Inhibitor for GA Growth

Novel C5 Inhibitor for GA Growth

Karl Csaky, MD, PhD

OPTIC Study Data

OPTIC Study Data

Arshad M. Khanani, MD

PALADIN Study in Diabetic Eye Disease

PALADIN Study in Diabetic Eye Disease

Victor H. Gonzalez, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARVO: 2020.